Cite Filings / RLAY / 0000932471-25-000992
Feed Companies Filings Check
Sign in
SCHEDULE 13G/A

Statement of Beneficial Ownership

Relay Therapeutics, Inc. · Filed 2025-07-29 · Acc 0000932471-25-000992

Documents 1

  • SCHEDULE 13G/A Statement of Beneficial Ownership , xslSCHEDULE_13G_X01/primary_doc.xml

Around this filing

  • 2025-08-14 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2025-07-30 4 Rahmer Peter sold 17,083 shares at an average $3.68 ($62,947)
  • 2025-07-30 4 Chief Financial Officer sold 20,081 shares at an average $3.69 ($74,000)
  • 2025-07-30 4 President, R&D sold 30,770 shares at an average $3.69 ($113,478)
  • 2025-07-30 4 Chief Legal Officer sold 19,913 shares at an average $3.68 ($73,378)
  • 2025-07-29 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2025-04-30 SCHEDULE 13G/A Statement of Beneficial Ownership

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G · T. Rowe Price Investment Management, Inc. 8.2%
  2. 2026-11-16 SCHEDULE 13G/A · SB Investment Advisers (UK) Limited 9.9%
Loading xslSCHEDULE_13G_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…